Literature DB >> 24068777

How safe is renal replacement therapy? A national study of mortality and adverse events contributing to the death of renal replacement therapy recipients.

Benjamin D Bray1, Jennifer Boyd, Conal Daly, Arthur Doyle, Ken Donaldson, Jonathan G Fox, Andrew Innes, Izhar Khan, Bruce Mackinnon, Robert K Peel, Ilona Shilliday, Keith Simpson, Graham A Stewart, Jamie P Traynor, Wendy Metcalfe.   

Abstract

BACKGROUND: Patients receiving treatment with renal replacement therapy (RRT) have high mortality, and ensuring patient safety in this population is difficult. We aimed to estimate the incidence and nature of medical adverse events contributing to the death of patients being treated with RRT.
METHODS: This population registry-based retrospective case review study included all patients being treated with RRT for established renal failure in Scotland and who died between 1 January 2008 and 30 June 2011. Deaths were reviewed by consultant nephrologists using a structured questionnaire to identify factors contributing to death occurring in both the inpatient and outpatient setting. Reviewers were able to use any information source deemed relevant, including paper and electronic clinical records, mortality and morbidity meetings and procurator fiscal (Scottish coroner) investigations. Deaths occurring in 2008 and 2009 where avoidable factors were identified that may have or did lead to death of a patient were subject to further review and root cause analysis, in order to identify recurrent themes.
RESULTS: Of 1551 deaths in the study period, 1357 were reviewed (87.5%). Cumulative RRT exposure in the cohort was 2.78 million person-days. RRT complications were the primary cause of death in 28 (2.1%). Health-care-associated infection had contributed to 9.6% of all deaths. In 3.5% of deaths, factors were identified which may have or did contribute to death. These were both organizational and human error related and were largely due to five main causes: management of hyperkalaemia, prescribing, out of hours care, infection and haemodialysis vascular access.
CONCLUSIONS: Adverse events contributing to death in RRT recipients mainly relate to the everyday management of common medical problems and not the technical aspects of RRT. Efforts to avoid harm in this population should address these ubiquitous causes of harm.

Entities:  

Keywords:  RRT; dialysis; mortality; safety; transplantation

Mesh:

Year:  2013        PMID: 24068777     DOI: 10.1093/ndt/gft197

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  Medical safety in the care of the person with end-stage kidney disease.

Authors:  John V Duronville; Clarissa J Diamantidis
Journal:  Semin Dial       Date:  2018-01-07       Impact factor: 3.455

2.  The impact of the COVID-19 pandemic on renal transplantation in the UK.

Authors:  Videha Sharma; Alex Shaw; Marcus Lowe; Angela Summers; David van Dellen; Titus Augustine
Journal:  Clin Med (Lond)       Date:  2020-05-25       Impact factor: 2.659

Review 3.  Maintaining safety in the dialysis facility.

Authors:  Alan S Kliger
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

4.  Improving patient safety in haemodialysis.

Authors:  Benjamin D Bray; Wendy Metcalfe
Journal:  Clin Kidney J       Date:  2015-05-09

5.  Development of a hemodialysis safety checklist using a structured panel process.

Authors:  Ziv Harel; Chaim M Bell; Samuel A Silver; Alison Thomas; Andrea Rathe; Pamela Robinson; Ron Wald
Journal:  Can J Kidney Health Dis       Date:  2015-02-12

6.  Feasibility of a hemodialysis safety checklist for nurses and patients: a quality improvement study.

Authors:  Alison Thomas; Samuel A Silver; Andrea Rathe; Pamela Robinson; Ron Wald; Chaim M Bell; Ziv Harel
Journal:  Clin Kidney J       Date:  2016-04-14

7.  Prolonged exposure to continuous renal replacement therapy in patients with acute kidney injury.

Authors:  Khaled Shawwa; Panagiotis Kompotiatis; Ankit Sakhuja; Paul McCarthy; Kianoush B Kashani
Journal:  J Nephrol       Date:  2021-06-23       Impact factor: 3.902

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.